Lung Cancer Signatures in Plasma Based on Proteome Profiling of Mouse Tumor Models

Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Cancer cell (Impact Factor: 23.52). 09/2011; 20(3):289-99. DOI: 10.1016/j.ccr.2011.08.007
Source: PubMed


We investigated the potential of in-depth quantitative proteomics to reveal plasma protein signatures that reflect lung tumor biology. We compared plasma protein profiles of four mouse models of lung cancer with profiles of models of pancreatic, ovarian, colon, prostate, and breast cancer and two models of inflammation. A protein signature for Titf1/Nkx2-1, a known lineage-survival oncogene in lung cancer, was found in plasmas of mouse models of lung adenocarcinoma. An EGFR signature was found in plasma of an EGFR mutant model, and a distinct plasma signature related to neuroendocrine development was uncovered in the small-cell lung cancer model. We demonstrate relevance to human lung cancer of the protein signatures identified on the basis of mouse models.

Download full-text


Available from: Karen S Kelly-Spratt, Oct 09, 2015
30 Reads
  • Source
    • "Next, we assessed the enrichment of membrane proteins in the cell surface compartment and of extracellular proteins in the media compartment. Localization of proteins was predicted using the Ingenuity Pathways Analysis (IPA; and protein abundance was estimated based on normalized MS/MS counts [17]. The subcellular localization demonstrated by mass spectrometric analysis and predictions from database analysis were concordant, particularly for abundant proteins (Supporting Information Fig. 1), indicating enrichment of cell surface or extracellular proteins based on cellular compartment. "
    [Show abstract] [Hide abstract]
    ABSTRACT: p53 is commonly mutated in lung adenocarcinoma. Mutant p53 loses wild-type function and some missense mutations further acquire oncogenic functions, while p53 wild-type may also induce pro-survival signaling. Therefore identification of signatures based on p53 mutational status has relevance to our understanding of p53 signaling pathways in cancer and identification of new therapeutic targets. To this end, we compared proteomic profiles of three cellular compartments (whole cell extract (WCE), cell surface, and media) from 28 human lung adenocarcinoma cell lines that differ based on p53 mutational status. In total, 11598 11569 and 9090 protein forms were identified in WCE, cell surface, and media, respectively. Bioinformatic analysis revealed that representative pathways associated with epithelial adhesion, immune and stromal cells, and mitochondrial function were highly significant in p53 missense mutations, p53 loss and wild-type p53 cell lines, respectively. Of note, mRNA levels of PGC1-α, a transcription co-activator that promotes mitochondrial oxidative phosphorylation and mitochondrial biogenesis, was substantially higher in p53 wild-type cell lines compared to either cell lines with p53 loss or with missense mutation. siRNA targeting PGC1-α inhibited cell proliferation in p53 wild-type cell lines, indicative of PGC1-α and its downstream molecules as potential therapeutic targets in p53 wild-type lung adenocarcinoma.This article is protected by copyright. All rights reserved
    Proteomics 12/2014; 14(23-24). DOI:10.1002/pmic.201400378 · 3.81 Impact Factor
  • Source
    • "Our findings showed that NPC2 is enhanced in lung adenocarcinoma tissue (Figure 3A). Proteomics analysis has also demonstrated that expression of NPC2 is increased in lung adenoma and pleural effusion [21,22]. Although it is not clear yet if NPC2 plays a role in lung adenocarcinoma, the presence of NPC2 protein in pleural effusion of patients with lung adenocarcinoma suggests that it may have a use as a potential diagnostic marker for lung cancer. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Niemann-Pick Type C2 (NPC2) plays an important role in the regulation of intracellular cholesterol homeostasis via direct binding with free cholesterol. However, little is known about the significance of NPC2 in cancer. In this study, we have pinpointed the impact of various different cancers on NPC2 expression. A series of anti-NPC2 monoclonal antibodies (mAbs) with the IgG2a isotype were generated and peptide screening demonstrated that the reactive epitope were amino acid residues 31-40 of the human NPC2 protein. The specificity of these mAbs was confirmed by Western blotting using shRNA mediated knock-down of NPC2 in human SK-Hep1 cells. By immunohistochemical staining, NPC2 is expressed in normal kidney, liver, breast, colon, lung, esophageal, uterine cervical, pancreatic and stomach tissue. Strong expression of NPC2 was found in the distal and proximal convoluted tubule of kidney and the hepatocytes of liver. Normal esophageal, uterine cervical, pancreatic, stomach, breast, colon and lung tissue stained moderately to weakly. When compared to their normal tissue equivalents, NPC2 overexpression was observed in cancers of the breast, colon and lung. Regarding to breast cancer, NPC2 up-regulation is associated with estrogen receptor (-), progesterone receptor (-) and human epidermal growth factor receptor (+). On the other hand, NPC2 was found to be down-regulated in renal cell carcinoma, liver cirrhosis and hepatoma tissues. By antigen-capture enzyme immunoassay ELISA, the serum NPC2 is increased in patients with cirrhosis and liver cancer. According to western blot data, the change of glycosylated pattern of NPC2 in serum is associated with cirrhosis and liver cancer. To the best of our knowledge, this is the first comprehensive immunohistochemical and serological study investigating the expression of NPC2 in a variety of different human cancers. These novel monoclonal antibodies should help with elucidating the roles of NPC2 in tumor development, especially in liver and breast cancers.
    PLoS ONE 10/2013; 8(10):e77586. DOI:10.1371/journal.pone.0077586 · 3.23 Impact Factor
  • Source
    • "Recently , Taguchi et al . performed quantitative MS to profile plasma proteomes of four genetically engineered mouse models of lung cancer and models of pancreatic , ovarian , co - lon , prostate , and breast cancer and two models of inflamma - tion ( Taguchi et al . , 2011 ) . The authors identified protein signatures that distinguish lung cancer from other cancers or inflammation . Remarkably , they obtained concordant results in human lung cancer cell lines , in patients with lung cancer at the time of diagnosis , and in asymptomatic individuals prior to diagnosis . This study demonstrated the utility o"
    [Show abstract] [Hide abstract]
    ABSTRACT: Lung cancer is the leading cause of cancer death in men and women in Western nations, and is among the deadliest cancers with a 5-year survival rate of 15%. The high mortality caused by lung cancer is attributable to a late-stage diagnosis and the lack of effective treatments. So, it is crucial to identify new biomarkers that could function not only to detect lung cancer at an early stage but also to shed light on the molecular mechanisms that underlie cancer development and serve as the basis for the development of novel therapeutic strategies. Considering that DNA-based biomarkers for lung cancer showed inadequate sensitivity, specificity, and reproducibility, proteomics could represent a better tool for the identification of useful biomarkers and therapeutic targets for this cancer type. Among the proteomics technologies, the most powerful tool is mass spectrometry. In this review, we describe studies that use mass spectrometry-based proteomics technologies to analyze tumor proteins and peptides, which might represent new diagnostic, prognostic, and predictive markers for lung cancer. We focus in particular on those findings that hold promise to impact significantly on the clinical management of this disease. © 2012 Wiley Periodicals, Inc. Mass Spec Rev.
    Mass Spectrometry Reviews 03/2013; 32(2). DOI:10.1002/mas.21355 · 7.71 Impact Factor
Show more